Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis
Authors:
- Basanta Sharma PaudelBPBasanta Sharma Paudel
- Sandesh Raman ParajuliSPSandesh Raman Parajuli
- Krishna DahalKDKrishna Dahal
- Sangam ShahSSSangam Shah
- Madhur BhattaraiMBMadhur Bhattarai
- Bidisha BaralBBBidisha Baral
- Bibek KarkiBKBibek Karki
- Bibhusan BasnetBBBibhusan Basnet
- Ranjit SahRanjit Sah
- Amit KhanalAKAmit Khanal
Open Access
- 26 December 2025
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (52) , e46671
Abstract
Background: Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly prescribed for diabetes mellitus and weight loss, often cause gastrointestinal side effects in both their oral and injectable forms. Recently, oral non-peptide GLP-1 receptor agonists like danuglipron and orforglipron, which are smaller and more stable, have been investigated. This study analyzes the gastrointestinal side effects of these newer, smaller molecules. Methods: We performed a systematic review of the literature databases like PubMed, Cochrane, Embase, and clinicaltrials.gov until November 2023. Data related to different doses of oral danuglipron and orforglipron and their gastrointestinal side effects including nausea, vomiting, constipation, diarrhea, eructation, and dyspepsia were obtained. Analysis was done using RevMan v5.4 (The Cochrane Collaboration, Copenhagen, Denmark). Results: We included a total of 4 studies of which 2 each were for danuglipron and orforglipron. The oral doses of orforglipron studied were 12 mg, 24 mg, 36 mg, and 45 mg, with nausea being the most common side effect in all groups. For the 45 mg dose of orforglipron, the odds ratio (OR) was 4.41 (95% CI: 2.90–6.71), while the 36 mg dose had an OR of 3.99 (95% CI: 2.22–7.18). The OR for the 24 mg dose was 5.66 (95% CI: 3.39–9.45), and the 12 mg dose showed an OR of 5.06 (95% CI: 3.31–7.73). Oral danuglipron at doses of 80 mg and 120 mg were also studied. The 120 mg dose of danuglipron had a pooled OR of 4.38 (95% CI: 2.30–8.34) while the 80 mg dose had an OR of 3.69 (95% CI: 1.77–7.67) indicating a significant decrease in gastrointestinal side effects. Conclusion: Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists were widely reported but less frequent compared to placebo/ standard treatment. There was no significant dose-dependent increase in the side effects of these medications.Keywords
This publication has 27 references indexed in Scilit:
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 DiabetesJAMA, 2015
- Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysisThe Lancet, 2014
- Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trialsDiabetes, Obesity and Metabolism, 2013
- Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) TrialsThe Journal of Clinical Endocrinology & Metabolism, 2011
- An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the futureDiabetes, Obesity and Metabolism, 2011
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled studyThe Lancet, 2009
- Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)Diabetic Medicine, 2009
- The incretin system and its role in type 2 diabetes mellitusMolecular and Cellular Endocrinology, 2009
- Measuring inconsistency in meta-analysesBMJ, 2003
- Bias in meta-analysis detected by a simple, graphical testBMJ, 1997